FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype

This publication has 10 references indexed in Scilit:

• Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
  Blood, 2002
• The roles of FLT3 in hematopoiesis and leukemia
  Blood, 2002
• Comparison of idarubicin + ara-C–, fludarabine + ara-C–, and topotecan + ara-C–based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
  Blood, 2001
• High-dose chemotherapy in high-risk myelodysplastic syndrome
  Cancer, 2001
• The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
  Blood, 2001
• FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
  Blood, 2001
• Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
  Blood, 2001
• Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
  Blood, 2001
• FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
  British Journal of Haematology, 2000
• Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene
  Leukemia, 2000